The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase II as Topic
  • Female
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Hydroxamic Acids / therapeutic use*
  • Indoles / pharmacology
  • Indoles / therapeutic use*
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Panobinostat
  • Sex Cord-Gonadal Stromal Tumors / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Panobinostat